Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer
Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer
Purpose: radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung cancer patients receiving concurrent chemotherapy. Therefore, we investigated the potential of bone marrow sparing with protons for esophageal tumors.
Methods and materials: twenty-one patients with mid-esophageal cancer who had undergone conformal radiation therapy (3D50) were selected. Two surrogates for bone marrow were created by outlining the thoracic bones (bone) and only the body of the thoracic vertebrae (TV) in Eclipse. The percentage of overlap of the TV with the planning treatment volume was recorded for each patient. Additional plans were created retrospectively, including a volumetric modulated arc therapy (VMAT) plan with the same dose as for 3D50; a VMAT SIB plan with a dose prescription of 62.5 Gy to the high-risk subregion within the planning treatment volume; a reoptimized TV-sparing VMAT plan; and a proton therapy plan with the same SIB dose prescription. The bone and TV dose metrics were recorded and compared across all plans and variations with respect to PTV and percentage of overlap for each patient.
Results: the 3D50 plans showed the highest bone mean dose and TV percentage of volume receiving ≥30 Gy (V30Gy) for each patient. The VMAT plans irradiated a larger bone V10Gy than did the 3D50 plans. The reoptimized VMAT62.5 VT plans showed improved sparing of the TV volume, but only the proton plans showed significant sparing for bone V10Gy and bone mean dose, especially for patients with a larger PTV.
Conclusions: the results of the present study have shown that proton therapy can reduced bone marrow toxicity.
729-737
Warren, Samantha
4a77820d-3875-4b74-8366-6b3be039b858
Hurt, Christopher N.
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Crosby, Thomas
03643ef4-1539-4a22-914d-b3da1eaa67e8
Partridge, Mike
256a0f46-9740-4251-998f-eef062e896ea
Hawkins, Maria A.
fe46c6fb-a77c-4308-8861-48b34a65c2f3
20 September 2017
Warren, Samantha
4a77820d-3875-4b74-8366-6b3be039b858
Hurt, Christopher N.
bf8b37a0-8f08-4b47-b3f3-6fc65f7ab87f
Crosby, Thomas
03643ef4-1539-4a22-914d-b3da1eaa67e8
Partridge, Mike
256a0f46-9740-4251-998f-eef062e896ea
Hawkins, Maria A.
fe46c6fb-a77c-4308-8861-48b34a65c2f3
Warren, Samantha, Hurt, Christopher N., Crosby, Thomas, Partridge, Mike and Hawkins, Maria A.
(2017)
Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer.
International Journal of Radiation Oncology*Biology*Physics, 99 (3), .
(doi:10.1016/j.ijrobp.2017.07.025).
Abstract
Purpose: radiation therapy dose escalation using a simultaneous integrated boost (SIB) is predicted to improve local tumor control in esophageal cancer; however, any increase in acute hematologic toxicity (HT) could limit the predicted improvement in patient outcomes. Proton therapy has been shown to significantly reduce HT in lung cancer patients receiving concurrent chemotherapy. Therefore, we investigated the potential of bone marrow sparing with protons for esophageal tumors.
Methods and materials: twenty-one patients with mid-esophageal cancer who had undergone conformal radiation therapy (3D50) were selected. Two surrogates for bone marrow were created by outlining the thoracic bones (bone) and only the body of the thoracic vertebrae (TV) in Eclipse. The percentage of overlap of the TV with the planning treatment volume was recorded for each patient. Additional plans were created retrospectively, including a volumetric modulated arc therapy (VMAT) plan with the same dose as for 3D50; a VMAT SIB plan with a dose prescription of 62.5 Gy to the high-risk subregion within the planning treatment volume; a reoptimized TV-sparing VMAT plan; and a proton therapy plan with the same SIB dose prescription. The bone and TV dose metrics were recorded and compared across all plans and variations with respect to PTV and percentage of overlap for each patient.
Results: the 3D50 plans showed the highest bone mean dose and TV percentage of volume receiving ≥30 Gy (V30Gy) for each patient. The VMAT plans irradiated a larger bone V10Gy than did the 3D50 plans. The reoptimized VMAT62.5 VT plans showed improved sparing of the TV volume, but only the proton plans showed significant sparing for bone V10Gy and bone mean dose, especially for patients with a larger PTV.
Conclusions: the results of the present study have shown that proton therapy can reduced bone marrow toxicity.
Text
1-s2.0-S036030161733609X-main
- Version of Record
More information
Accepted/In Press date: 18 July 2017
e-pub ahead of print date: 29 July 2017
Published date: 20 September 2017
Identifiers
Local EPrints ID: 488222
URI: http://eprints.soton.ac.uk/id/eprint/488222
ISSN: 0360-3016
PURE UUID: cb7e069b-2e16-4716-b5a5-c2f0ee80d9fd
Catalogue record
Date deposited: 18 Mar 2024 17:58
Last modified: 23 Mar 2024 03:13
Export record
Altmetrics
Contributors
Author:
Samantha Warren
Author:
Christopher N. Hurt
Author:
Thomas Crosby
Author:
Mike Partridge
Author:
Maria A. Hawkins
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics